New oral anticoagulants and oculoplastic surgery.

Edsel Ing, James Douketis

Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2014;49(2):123-7

PMID: 24767215

Full Text on Elsevier Science View on PubMed

Abstract

The use of oral anticoagulants is increasing because of the rising prevalence of atrial fibrillation and other cardiovascular diseases that occur in an aging population. In the last decade, several new oral anticoagulants have emerged, comprising the direct thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban and rivaroxaban. Although these new anticoagulants may not affect clear corneal cataract surgery, their use will impact the management of patients having eyelid, orbital, and nasolacrimal procedures. The objective of this review is to provide a concise and practical approach to the perioperative management of patients who require an oculoplastic procedure and are receiving these new anticoagulants.

Address: Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont. Electronic address: [email protected].; Department of Medicine, McMaster University, Hamilton, Ont.

DOI: 10.1016/j.jcjo.2013.11.007

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Other Literature Sources:

https://scite.ai/reports/24767215

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Oral, Anticoagulants, Benzimidazoles, Cardiovascular Diseases, Cataract Extraction, Dabigatran, Humans, Morpholines, Pyrazoles, Pyridones, Rivaroxaban, Surgery, Plastic, Thiophenes, beta-Alanine